John Libbey Eurotext

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement


Diagnostic value of Alzheimer's biomarkers in cerebrospinal fluid in dementia with Lewy body Volume 16, issue 2, Juin 2018


  • Figure 1
1 Hôpitaux Universitaire de Strasbourg, Laboratoire de biochimie et biologie moléculaire ; CNRS, Laboratoire de neurosciences cognitives et adaptatives (LNCA), UMR 7364, Strasbourg, France
2 Hôpitaux Universitaire de Strasbourg, Centre mémoire de ressource et de recherche (CMRR), Hôpital de jour, Pôle de gériatrie ; CNRS, laboratoire ICube UMR 7357 ; Fédération de médecine translationnelle de Strasbourg (FMTS), Équipe IMIS/Neurocrypto, Strasbourg, France
* Tirés à part

Dementia with Lewy body (DLB) is the second most common form of dementia after Alzheimer's disease (AD), accounting for 15% to 20% of neuropathologically defined cases. Two-thirds of the patients affected are not or misdiagnosed. In this review, we evaluate the discriminatory power of cerebrospinal fluid (CSF) biomarkers by focusing more specifically on differential diagnosis between DLB and AD. Thus, among the AD biomarkers (t-Tau, phospho-Tau181, Aβ42 and Aβ40) used routinely, t-Tau and phospho-Tau181 have shown excellent discrimination whatever the clinical stages severity. Aβ42 level is pathological in DLB patients at the demented stage, but is almost not impacted at the prodromal stage. Thus, globally the biological diagnosis on CSF basis makes it possible to separate the DLBs from the ADs.